TY  - JOUR
AU  - Kimmich, Christoph R
AU  - Terzer, Tobias
AU  - Benner, Axel
AU  - Hansen, Timon
AU  - Carpinteiro, Alexander
AU  - Dittrich, Tobias
AU  - Veelken, Kaya
AU  - Jauch, Anna
AU  - Huhn, Stefanie
AU  - Basset, Marco
AU  - Goldschmidt, Hartmut
AU  - Müller-Tidow, Carsten
AU  - Schönland, Stefan O
AU  - Hegenbart, Ute
TI  - Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
JO  - American journal of hematology
VL  - 96
IS  - 7
SN  - 1096-8652
CY  - New York, NY
PB  - Wiley-Liss
M1  - DKFZ-2021-00848
SP  - E253-E257
PY  - 2021
N1  - 2021 Jul 1;96(7):E253-E257 /Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
LB  - PUB:(DE-HGF)16
C6  - pmid:33844864
DO  - DOI:10.1002/ajh.26191
UR  - https://inrepo02.dkfz.de/record/168354
ER  -